Skip to content

Study · Animal study (in vivo) · mouse · 2023

7 results

The mitochondria-targeted small molecule SS31 delays progression of behavioral deficits by attenuating β-amyloid plaque formation and mitochondrial/synaptic deterioration in APP/PS1 mice.

Jia YL, Wang W, Han N, Sun HL, Dong FM, Song YX, Feng RF, Wang JH

Biochemical and biophysical research communications28 Feb 2023Cited by 13 (Europe PMC)

PMID37018887 (opens in a new tab)DOI10.1016/j.bbrc.2023.02.076 (opens in a new tab)PepBankPUB-37018887
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, long-term SS31 treatment reversed the elevated expression of Abeta40/Abeta42.

    In plain wordsIn mice with Alzheimer-like disease, long-term SS31 reversed the raised levels of amyloid-beta.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseHippocampal Abeta40/Abeta42 expression
    Study

    mousen: not reported in source

    APP/PS1 transgenic mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · long-termAs given in this study (mouse).

    Source sentences

    Summary
    The APP/PS1 transgenic mice exhibited elevated expression of Aβ40/Aβ42 and mitochondrial fission protein DLP1 and reduced expression of synaptophysin (SYN) and postsynaptic density protein 95 (PSD95) reductions, as well as increased levels of neuronal apoptosis and ROS in the hippocampus, and long-t…
    1 context sentence
    Summary · context
    Therefore, in this study we compared mitochondrial and synaptic changes, as well as the protective effects of SS31, in APP/PS1 transgenic mice and C57BL/6J control mice.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In APP/PS1 mice, long-term SS31 treatment reversed the elevated expression of the mitochondrial fission protein DLP1.

    In plain wordsIn mice with Alzheimer-like disease, long-term SS31 reversed the raised level of a mitochondrial fission protein.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMitochondrial fission protein DLP1
    Study

    mousen: not reported in source

    APP/PS1 transgenic mice
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    Dose not stated · long-termAs given in this study (mouse).

    Source sentences

    Summary
    The APP/PS1 transgenic mice exhibited elevated expression of Aβ40/Aβ42 and mitochondrial fission protein DLP1 and reduced expression of synaptophysin (SYN) and postsynaptic density protein 95 (PSD95) reductions, as well as increased levels of neuronal apoptosis and ROS in the hippocampus, and long-t…
    1 context sentence
    Summary · context
    Therefore, in this study we compared mitochondrial and synaptic changes, as well as the protective effects of SS31, in APP/PS1 transgenic mice and C57BL/6J control mice.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In APP/PS1 mice, long-term SS31 treatment reversed the reduced expression of synaptophysin.

    In plain wordsIn mice with Alzheimer-like disease, long-term SS31 reversed the lowered level of a synapse protein.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSynaptophysin expression
    Study

    mousen: not reported in source

    APP/PS1 transgenic mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · long-termAs given in this study (mouse).

    Source sentences

    Summary
    The APP/PS1 transgenic mice exhibited elevated expression of Aβ40/Aβ42 and mitochondrial fission protein DLP1 and reduced expression of synaptophysin (SYN) and postsynaptic density protein 95 (PSD95) reductions, as well as increased levels of neuronal apoptosis and ROS in the hippocampus, and long-t…
    1 context sentence
    Summary · context
    Therefore, in this study we compared mitochondrial and synaptic changes, as well as the protective effects of SS31, in APP/PS1 transgenic mice and C57BL/6J control mice.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In APP/PS1 mice, long-term SS31 treatment reversed the reduced expression of postsynaptic density protein 95.

    In plain wordsIn mice with Alzheimer-like disease, long-term SS31 reversed the lowered level of another synapse protein.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreasePSD95 expression
    Study

    mousen: not reported in source

    APP/PS1 transgenic mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · long-termAs given in this study (mouse).

    Source sentences

    Summary
    The APP/PS1 transgenic mice exhibited elevated expression of Aβ40/Aβ42 and mitochondrial fission protein DLP1 and reduced expression of synaptophysin (SYN) and postsynaptic density protein 95 (PSD95) reductions, as well as increased levels of neuronal apoptosis and ROS in the hippocampus, and long-t…
    1 context sentence
    Summary · context
    Therefore, in this study we compared mitochondrial and synaptic changes, as well as the protective effects of SS31, in APP/PS1 transgenic mice and C57BL/6J control mice.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, long-term SS31 treatment reversed the increased neuronal apoptosis in the hippocampus.

    In plain wordsIn mice with Alzheimer-like disease, long-term SS31 reversed the increase in nerve cell death in the hippocampus.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseNeuronal apoptosis in the hippocampus
    Study

    mousen: not reported in source

    APP/PS1 transgenic mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · long-termAs given in this study (mouse).

    Source sentences

    Summary
    The APP/PS1 transgenic mice exhibited elevated expression of Aβ40/Aβ42 and mitochondrial fission protein DLP1 and reduced expression of synaptophysin (SYN) and postsynaptic density protein 95 (PSD95) reductions, as well as increased levels of neuronal apoptosis and ROS in the hippocampus, and long-t…
    1 context sentence
    Summary · context
    Therefore, in this study we compared mitochondrial and synaptic changes, as well as the protective effects of SS31, in APP/PS1 transgenic mice and C57BL/6J control mice.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In APP/PS1 mice, long-term SS31 treatment reversed the increased reactive oxygen species levels in the hippocampus.

    In plain wordsIn mice with Alzheimer-like disease, long-term SS31 reversed the rise in reactive oxygen species in the hippocampus.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseHippocampal ROS
    Study

    mousen: not reported in source

    APP/PS1 transgenic mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · long-termAs given in this study (mouse).

    Source sentences

    Summary
    The APP/PS1 transgenic mice exhibited elevated expression of Aβ40/Aβ42 and mitochondrial fission protein DLP1 and reduced expression of synaptophysin (SYN) and postsynaptic density protein 95 (PSD95) reductions, as well as increased levels of neuronal apoptosis and ROS in the hippocampus, and long-t…
    1 context sentence
    Summary · context
    Therefore, in this study we compared mitochondrial and synaptic changes, as well as the protective effects of SS31, in APP/PS1 transgenic mice and C57BL/6J control mice.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, SS31 treatment reversed the cognitive impairments.

    In plain wordsIn mice with Alzheimer-like disease, SS31 reversed their cognitive impairments.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCognitive impairment
    Study

    mousen: not reported in source

    APP/PS1 transgenic mice
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · long-termAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, the cognitive impairments observed in APP/PS1 transgenic mice were reversed by SS31 treatment.
    1 context sentence
    Summary · context
    Therefore, in this study we compared mitochondrial and synaptic changes, as well as the protective effects of SS31, in APP/PS1 transgenic mice and C57BL/6J control mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.